BCT Insider Trading (BriaCell Therapeutics)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$97,497.40
Insider Selling (Last 12 Months): C$0.00
BriaCell Therapeutics Share Price & Price History
Current Price: C$10.60
Price Change: ▼ Price Decrease of -0.42 (-3.81%)
As of 12/30/2021 01:00 AM ET
Copper More Critical than Lithium?
From Investing Trends | Ad
Lithium may have grabbed the headlines as a key material in building electric vehicles (EVs). But so is copper. And copper's importance in the new green economy goes far beyond EVs. Copper is critical in building wind turbines and solar panels. It's key to power lines and upgrading the national grid. Analysts say we're facing a 10-million-ton shortfall if new copper mines are not found.
See How To Can Benefit From New Copper Discoveries
BriaCell Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 7/14/2022 | William Williams | Director | Buy | 27,272 | C$3.58 | C$97,497.40 | 27,272 | |
| 4/23/2021 | Gadi Levin | Senior Officer | Buy | 2,000 | C$5.09 | C$10,187.76 | 2,810 | |
| 4/23/2021 | William Williams | Director | Buy | 82,750 | C$4.14 | C$342,982.20 | 149,636 | |
Copper More Critical than Lithium?
From Investing Trends | Ad
Lithium may have grabbed the headlines as a key material in building electric vehicles (EVs). But so is copper. And copper's importance in the new green economy goes far beyond EVs. Copper is critical in building wind turbines and solar panels. It's key to power lines and upgrading the national grid. Analysts say we're facing a 10-million-ton shortfall if new copper mines are not found.
See How To Can Benefit From New Copper Discoveries
SEC Filings (Institutional Ownership Changes) for BriaCell Therapeutics (CVE:BCT)
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Read More on BriaCell Therapeutics
Today's Range
Now: C$10.60
Low: C$10.60
High: C$11.07
50 Day Range
MA: C$10.60
Low: C$10.60
High: C$10.60
52 Week Range
Now: C$10.60
Volume
3,402 shs
Average Volume
12,671 shs
Market Capitalization
C$168.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of BriaCell Therapeutics?
